Chronic Prostatitis/Chronic Pelvic Pain Syndromes
Conditions
Interventions
Intervention group:Latent myofascial trigger points injection
Control group:Oral medication(Levofloxacin combined with Tamsulosin)
Sponsors
Qilu Hospital, Cheeloo College of Medicine, Shandong University
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1)18 to 50 years old (2)NIH-CPSI total score greater than 15 (3)with a history of pain or discomfort perceived in the prostate region with no other lower urinary tract pathology for a minimum of 3 months.The main clinical manifestations were pain around the prostate as the center of the radiation, and pain, heaving or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral, medial thigh and other parts. Abnormal urination manifested as frequent urination, urgent urination, urination pain, urethral burning, residual urination or white discharge from the urethra in the morning, at the end of urination or defecation. Neuropsychiatric symptoms include dizziness and tinnitus, insomnia and dreams, anxiety and depression, and even sexual dysfunction such as impotence and premature ejaculation. (4)Volunteer to participate in this trial and sign the informed consent
Exclusion criteria
Exclusion criteria: (1)Bladder outlet obstruction, overactive bladder syndrome, neurogenic bladder, interstitial cystitis, cystitis glandularis, sexually transmitted diseases, bladder tumors including in situ carcinoma, prostate cancer, urinary tract infections, other types of prostatitis. (2)Residual urine =100mL on abdominal ultrasound. (3)Symptomatic urinary tract infections and organic diseases of the urinary system. (4)Use of medications to relieve symptoms of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), or non-pharmacological therapies for CP/CPPS (acupuncture, biofeedback); current use of medications affecting lower urinary tract function. (5)Conditions affecting lower urinary tract function, such as multiple sclerosis, senile dementia, Parkinson’s disease, spinal cord injury, cauda equina injury, stroke, and multiple system atrophy. (6)Allergies or hypersensitivity to lidocaine or vitamin B12. (7)Severe heart, lung, brain, liver, kidney, hematologic disorders, mental illness, and significant cognitive impairment. (8)Any other exclusions that meet the NIH consensus criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The National Institute of Health Chronic Prostatitis Symptom Index, NIH-CPSI; | — |
Secondary
| Measure | Time frame |
|---|---|
| The National Institute of Health Chronic Prostatitis Symptom Index, NIH-CPSI;visual analogue scale,VAS;Hospital anxiety and depression scale,HADS;European Quality ofLife Five Dimension Five Level Scale Questionnaire, EQ-5D-5L;response rate; | — |
Countries
China
Contacts
Public ContactFeng Qi
Qilu Hospital, Cheeloo College of Medicine, Shandong University
Outcome results
None listed